Medtronic Receives FDA Approval for World's First Hybrid Closed Loop System for People with Type 1 Diabetes

Sept. 28, 2016

DUBLIN - Sept. 28, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed® 670G system - the first Hybrid Closed Loop insulin delivery system approved anywhere in the world. Featuring the company's most advanced algorithm - SmartGuard(TM) HCL - the system is the latest innovation in Medtronic's phased approach toward developing a fully automated, closed loop system. Medtronic is committed to simplifying and improving diabetes management through the advancement of smart algorithms that achieve greater glucose control with reduced patient input. Through SmartGuard HCL, the system builds on Medtronic's industry leading algorithms to offer therapy customization so patients and providers can choose from increasing levels of automation that best fit their diabetes management needs.

Read more >

Medtronic Announces First Live Experience of Sugar.IQ with Watson for People Living with Diabetes c

Sept. 27, 2016

DUBLIN and SANTA CLARA, Calif. - Sept. 27, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that Sugar.IQ with Watson, the first-of-its-kind cognitive app that helps detect important patterns and trends for people with diabetes, is now in live use for the first time. With app development now completed, the first users are participating in real-world testing of the final release candidate. Developed with IBM Watson Health, the Sugar.IQ app will be demonstrated at the 10th Annual Health 2.0 Fall Conference in Santa Clara, Calif. The Sugar.IQ app uses real-time continuous glucose monitoring (CGM) and insulin information from Medtronic pumps and glucose sensors. It leverages IBM cognitive computing power, combined with Medtronic's expertise in diabetes, to find hidden patterns in diabetes data and will offer real-time and personalized insights so that people with diabetes can spend less time worrying about their data and have more freedom to simply enjoy life. The app will provide individualized guidance in understanding and helping to manage elements of daily diabetes decisions by creating a single platform that brings together relevant data and provides context and insights.

Read more >

Medtronic Announces U.S. Launch of the MiniMed® 630G System with New User-Friendly Insulin Pump Design and SmartGuard(TM) Technology

Aug 11, 2016

DUBLIN - August 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of its MiniMed 630G system with SmartGuard technology FDA approved for the treatment of people with diabetes mellitus sixteen years of age and older. The MiniMed 630G features a new insulin pump hardware platform and new user-friendly design that combines personalized diabetes management with industry-leading clinical performance. The MiniMed 630G system is the newest member of the MiniMed family-the most prescribed integrated insulin delivery system brand in the world.

Read more >

Medtronic Converts 125 Million Patient Days of Data Into Personalized Insights That Improve Diabetes Management

June 10, 2016

DUBLIN and NEW ORLEANS - June 10, 2016 - Delivering on its vision to transform care for the millions currently living with diabetes through intelligent data, Medtronic plc (NYSE:MDT) announced new product developments and technology partnerships at the American Diabetes Association (ADA) 76th Scientific Sessions that will create meaningful insights for providers and people with diabetes.

Read more >

Medtronic and Qualcomm Collaborate to Aim to Improve Care and Health Outcomes for People with Type 2 Diabetes

May 25, 2016

Dublin and San Diego – May 25, 2016 - Medtronic plc (NYSE:MDT) and Qualcomm Incorporated (NASDAQ:QCOM) through its wholly-owned subsidiary, Qualcomm Life, Inc., today announced a global, multi-year collaboration to jointly develop future generation continuous glucose monitoring (CGM) systems that aim to improve health outcomes for people with diabetes. By giving insights to doctors and people with type 2 diabetes concerning glucose levels, the companies intend to enable more informed care, especially for those who do not have control of their diabetes today. The collaboration seeks to leverage Medtronic's market-leadership in diabetes management and Qualcomm Life's expertise in developing reference designs for wireless, single-use and small integrated modules to create more affordable, easier-to-use CGM systems, including a new sensor and smaller design that can provide near real-time and retrospective glucose data.

Read more >